Vivtex

Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation

Novo Nordisk (NYSE: NVO) announced a strategic partnership with Vivtex Corporation to co-develop next‑generation oral biologic...